Here’s a shocking fact: the number of shares and voting rights for a cutting-edge biopharmaceutical company can reveal more about its future than you might think. But here’s where it gets controversial—how these numbers are calculated and what they mean for stakeholders can spark heated debates. As of October 31st, 2025, ADOCIA SA, a French clinical-stage biopharmaceutical company headquartered in Lyon, has released its latest figures, and they’re worth a closer look.
ADOCIA, listed on Euronext Paris (ticker: ADOC; ISIN: FR0011184241), is no ordinary player in the healthcare sector. Focused on tackling metabolic diseases like diabetes and obesity, the company boasts a robust pipeline of innovative therapies. And this is the part most people miss—their proprietary technology platforms, such as BioChaperone®, AdOral®, AdoShell®, and AdoGel®, are revolutionizing drug delivery and treatment approaches. But let’s dive into the numbers first.
As of the end of October 2025, ADOCIA reported:
- Total outstanding shares: 18,298,423
- Total theoretical voting rights: 20,389,198
- Total exercisable voting rights: 20,381,093
Why does this matter? The theoretical voting rights, calculated under French regulations (Article 223-11 of the AMF General Regulation), include all shares with voting rights, even those temporarily suspended. This figure is crucial for determining shareholding thresholds. On the other hand, exercisable voting rights exclude shares with suspended rights, such as those held by the company under a liquidity agreement. Here’s the kicker: this distinction can significantly impact shareholder influence and corporate decision-making.
Now, let’s talk about ADOCIA’s broader impact. With over 25 patent families and a team of 80 employees, the company is a powerhouse of innovation. Their BioChaperone® technology, for instance, is paving the way for next-generation insulins and hormone combinations. Meanwhile, AdoShell® is making waves in cell transplantation, offering immunoprotection for pancreatic cell transplants. But here’s a thought-provoking question: As ADOCIA continues to push boundaries, will its focus on diabetes and obesity limit its potential in other therapeutic areas? Or is this specialization its greatest strength?
In a world where metabolic diseases are on the rise, ADOCIA’s work is more critical than ever. But as shareholders and observers, we must ask: Are these numbers a sign of steady growth, or do they hint at untapped opportunities? Share your thoughts in the comments—let’s spark a conversation about the future of biopharmaceutical innovation.
